Hygeia Completes $1M Series A

Erin Kutz4/19/10

Hygeia Therapeutics, a Holden, MA, developer of hormone-based topical drugs, has closed a $1 million round of Series A funding, the company announced today. Hygeia did not reveal the investors in the round, but said the funding will go to testing its topical synthetic estrogen drug designed to treat age-related skin thinning, and will fuel the development of a topical anti-androgen drug.

Erin Kutz is an Associate Editor for Xconomy. You can reach her by e-mail at ekutz@xconomy.com or by phone at (617) 252-0700, or follow her on Twitter at @erkutz.